keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg Clearance

keyword
https://www.readbyqxmd.com/read/29340620/delivery-of-tapasin-modified-ctl-epitope-peptide-via-cytoplasmic-transduction-peptide-induces-ctls-by-jak-stat-signaling-pathway-in-vivo
#1
Shanshan Wu, Xiaohua Chen, Yuyan Tang, Yi Zhang, Dan Li, Jie Chen, Jieling Wang, Zhenghao Tang, Guoqing Zang, Yongsheng Yu
Hepatitis B virus (HBV)-specific cytotoxic T lymphocytes (CTLs) play a vital role in viral control and clearance. Recent studies have elucidated that Tapasin, an endoplasmic reticulum chaperone, is a well-known molecule that appears to be essential in peptide-loading process. The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway plays an important role in immune response regulation and cytokines secretion. We have previously verified that fusion protein CTP-HBcAg18-27-Tapasin could facilitate the maturation of bone marrow derived dendritic cells and enhance specific CTLs responses in vitro, which might be associated with the activation of JAK/STAT signaling pathway...
January 11, 2018: Acta Biochimica et Biophysica Sinica
https://www.readbyqxmd.com/read/29306503/a-mouse-model-with-age-dependent-immune-response-and-immune-tolerance-for-hbv-infection
#2
Xuerui Yi, Youcheng Yuan, Na Li, Lu Yi, Cuiling Wang, Ying Qi, Liang Gong, Guangze Liu, Xiangping Kong
BACKGROUND: Viral clearance of human HBV infection largely depends on the age of exposure. Thus, a mouse model with age-dependent immune response and immune-tolerance for HBV infection was established. METHODS: HBVRag1 mice were generated by crossing Rag1-/- mice with HBV-Tg mice. Following adoptive transfer of splenocytes adult (8-9 weeks old) and young (3 weeks old) HBVRag1 mice were named as HBVRag-ReA and HBVRag-ReY mice respectively. The biochemical parameters that were associated with viral load and immune function, as well as the histological evaluation of the liver tissues between the two mouse models were detected...
January 3, 2018: Vaccine
https://www.readbyqxmd.com/read/29246694/effects-of-diabetes-and-glycemia-control-on-risk-of-hepatocellular-carcinoma-after-seroclearance-of-hepatitis-b-surface-antigen
#3
Terry Cheuk-Fung Yip, Vincent Wai-Sun Wong, Henry Lik-Yuen Chan, Yee-Kit Tse, Alice Pik-Shan Kong, Kelvin Long-Yan Lam, Grace Chung-Yan Lui, Grace Lai-Hung Wong
BACKGROUND & AIMS: Diabetes is associated with a 2-fold increase in risk of hepatocellular carcinoma (HCC) among patients with chronic hepatitis B virus (HBV) infection. However, we know little about the effect of diabetes on HCC risk after seroclearance of hepatitis B surface antigen (HBsAg). We evaluated the effect of diabetes and glycemic control on HCC development after HBsAg seroclearance in a population-wide study in Hong Kong. METHODS: We performed a retrospective study of 4568 patients with chronic HBV infection who cleared HBsAg from January 2000 through August 2016, using the Clinical Data Analysis and Reporting System of the Hospital Authority, Hong Kong...
December 12, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29226133/circulating-interferon-%C3%AE-3-responsiveness-to-hbv-vaccination-and-hbv-hcv-infections-in-haemodialysis-patients
#4
Alicja E Grzegorzewska, Monika K Świderska, Adrianna Mostowska, Paweł P Jagodziński
The IFN-λ3 gene (IFNL3) plays a role in HCV clearance. We investigated circulating IFN-λ3 and IFNL3 SNPs in haemodialysis patients who differed in their response to HBV vaccination and their HBV/HCV infection status. In 201 patients, plasma IFN-λ3 was determined using ELISA. IFNL3 SNPs (rs12979860, rs8099917) were genotyped using HRM analysis. Differences in IFN-λ3 levels were shown between responders and nonresponders to HBV vaccination and between HBsAg-positive patients and those who developed anti-HBs after infection and became HBsAg negative...
2017: BioMed Research International
https://www.readbyqxmd.com/read/29202690/distinct-patterns-of-serum-hepatitis-b-core-related-antigen-during-the-natural-history-of-chronic-hepatitis-b
#5
Zhan-Qing Zhang, Xiao-Nan Zhang, Wei Lu, Yan-Bing Wang, Qi-Cheng Weng, Yan-Ling Feng
BACKGROUND: The current clinical practice on chronic hepatitis B (CHB) requires better on-treatment monitoring of viral persistence. Quantified assays for hepatitis B surface antigen (HBsAg) and core-related antigen (HBcrAg) hold promise for further optimization of therapy. Here, we aimed to characterize HBcrAg during the natural course of CHB. METHODS: Four-hundred and forty four treatment naïve CHB patients, who all underwent liver histology examination, were enrolled in this cross-sectional study...
December 4, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/29180321/-a-recombinant-adenovirus-vector-carrying-murine-interleukin-21-gene-controls-chronic-hbv-infection-in-mice
#6
Xue-Ping Gao, Yang Zhou, Xin-Chun Zheng, Xuan Yi, Li-Bo Tang, Jin-Lin Hou, Yong-Yin Li
OBJECTIVE: To investigate the effect of an adenovirus vector containing murine interleukin-21 gene (Ad-GFP-mIL-21) in virus clearance and on the production of HBV-specific antibodies in mice with persistent HBV infection. METHODS: ELISA and Western blot analysis were used to detect the expression of mIL-21 in the supernatant and cytoplasm of cultured HepG2.2.15 cells after infection by Ad-GFP-mIL-21. Mouse models of chronic HBV infection established by in vivo transduction with rAAV8-1...
November 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/29149205/kir-content-genotypes-associate-with-carriage-of-hepatitis-b-surface-antigen-e-antigen-and-hbv-viral-load-in-gambians
#7
Louis-Marie Yindom, Maimuna Mendy, Christopher Bodimeade, Caroline Chambion, Peter Aka, Hilton C Whittle, Sarah L Rowland-Jones, Robert Walton
BACKGROUND: Hepatocellular carcinoma (HCC) causes over 800,000 deaths worldwide annually, mainly in low income countries, and incidence is rising rapidly in the developed world with the spread of hepatitis B (HBV) and C (HCV) viruses. Natural Killer (NK) cells protect against viral infections and tumours by killing abnormal cells recognised by Killer-cell Immunoglobulin-like Receptors (KIR). Thus genes and haplotypes encoding these receptors may be important in determining both outcome of initial hepatitis infection and subsequent chronic liver disease and tumour formation...
2017: PloS One
https://www.readbyqxmd.com/read/29131246/study-on-the-distribution-of-cd8-memory-t-cell-subsets-and-ifn-%C3%AE-level-during-the-spontaneous-clearance-of-hepatitis-b-virus-in-patients-with-chronic-hepatitis-b-virus-infection
#8
X-J Ma, X-F Chen, W-L Chen, R Chen, J Huang, X-D Luo, J-Y Liao, X-P Chen
OBJECTIVE: To study the alteration of CD8+ memory T cell subsets under different immune statuses during the spontaneous clearance of hepatitis B virus (HBV) in Chinese patients with chronic HBV infection. PATIENTS AND METHODS: We analyzed Chinese patients with chronic HBV infection including 10 patients with Hepatitis B surface Antigen (HBsAg) spontaneous seroconversion, 25 patients with Hepatitis B virus e Antigen (HBeAg) spontaneous seroconversion, 25 patients with chronic hepatitis B (CHB), and 25 chronic HBV carriers...
October 2017: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29108132/incidence-and-predictors-of-hbsag-seroclearance-after-cessation-of-nucleos-t-ide-analogue-therapy-in-hbeag-negative-chronic-hepatitis-b
#9
Wen-Juei Jeng, Yi-Cheng Chen, Rong-Nan Chien, I-Shyan Sheen, Yun-Fan Liaw
Hepatitis B s antigen (HBsAg) loss is a rare event during nucleos(t)ide analogue (Nuc) therapy. Limited data suggest that stopping Nuc therapy may increase HBsAg loss rate in hepatitis B e antigen (HBeAg) negative patients. A large study was conducted to investigate this issue in more detail. Of the 1075 HBeAg-negative patients treated with Nuc for 156 (61-430) weeks, 6 showed HBsAg seroclearance during treatment at an estimated annual incidence of 0.15%. Of the patients who remained HBsAg seropositive, 691 (52...
November 6, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29082651/comparison-of-208-week-sequential-therapy-with-telbivudine-and-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24%C3%A2-weeks-of-peg-ifn%C3%AE-2a-therapy-an-open-labelled-randomized-controlled-real-life-trial
#10
X D Luo, X F Chen, Y Zhou, X P Chen
The purpose of the study was to compare the efficacy and safety of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy. This was an open-label, randomized, controlled, "real-life" trial. HBeAg-positive CHB patients with serum HBV DNA ≥5.0 lg IU/mL and a < 1 lg IU/mL decline of HBsAg level from baseline who underwent at least 24 weeks of Peg-IFNα-2a therapy were included. Enrolled patients were randomized to receive either telbivudine (600 mg/d, n = 95) or entecavir (0...
November 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29062901/new-directions-in-hepatitis-b-therapy-research
#11
REVIEW
Marta Lewandowska, Anna Piekarska
Chronic hepatitis B treatment is available for a long period, allowing disease control and infection suppression, but it is rarely responsible for HBsAg clearance. None of the drugs available aim at cccDNA, the obstacle in HBV infection eradication. Complications related to CHB, such as liver insufficiency, cirrhosis, and hepatocellular carcinoma are reduced in conditions of good viremia suppression, but still exist even after HBsAg seroclearance, what makes a need for urgent forthcoming of new therapeutics...
September 2017: Clinical and experimental hepatology
https://www.readbyqxmd.com/read/29056007/-clinical-effect-of-156-week-telbivudine-sequential-therapy-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-response-to-pegylated-interferon-%C3%AE-2a-therapy
#12
X D Luo, X P Chen, X F Chen
Objective: To investigate the clinical effect of 156-week telbivudine sequential therapy in HBeAg-positive chronic hepatitis B patients with suboptimal response to pegylated interferon-α-2a (Peg-IFN-α-2a) therapy. Methods: A total of 35 HBeAg-positive CHB patients with HBV DNA < 500 IU/ml who were treated with Peg-IFN-α-2a for 48 weeks and did not experience seroconversion of HBeAg were given telbivudine sequential therapy for 156 weeks. HBeAg clearance rate, HBeAg seroconversion rate, HBV DNA clearance rate, safety, and drug resistance rate were analyzed...
August 20, 2017: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/29052304/immunotherapy-for-hepatitis-b-in-the-direct-acting-anti-viral-era-reevaluating-the-thymosin-%C3%AE-1-efficacy-trials-in-light-of-a-combination-therapy-approach
#13
Paul H Naylor, Milton G Mutchnick
Hepatitis B virus (HBV) causes both acute and chronic hepatitis and infects large numbers of individuals worldwide. Unfortunately, prediction of typical clinical outcome is problematic and there is considerable variability in the frequency, duration and severity of disease progression. The mainstay of HBV treatment is directed towards the suppression of HBV replication by nucleos(t)ide analogs (NUCs). The use of immunomodulators such as α-Interferon and thymosin α1 can, in select patients, result in elimination of both HBsAg and HBeAg...
October 20, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29032635/prevalence-and-natural-course-of-occult-hepatitis-b-virus-infection-in-residents-of-two-communities-of-wuwei-city-gansu-province-china
#14
Xiaohui Wen, Haixia Su, Yang Wang, Zhongshu Pu, Jie Gao, Zhaohua Ji, Xiaojie Yuan, Xiaochun Li, Weilu Zhang, Lei Zhang, Yong Long, Yongping Yan, Zhongjun Shao
Occult hepatitis B infection (OBI) is characterized by serum hepatitis B surface antigen (HBsAg) negative and hepatitis B virus (HBV) DNA positive (HBsAg-/HBV DNA+). OBI in community-based populations has been scarcely investigated, and OBI outcomes remain unclear, especially in Wuwei, a region located in Northwest China. This region is one of the areas in China that has the highest prevalence of chronic HBV infection. A prospective study was performed in the general population of two towns of Wuwei from June 2011 to May 2014...
October 15, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28940887/association-of-human-leukocyte-antigen-polymorphisms-with-occult-hepatitis-b-virus-infection-in-a-shaanxi-han-population
#15
Tianju Wang, Chunmei Shen, Liping Chen, Sheng Liu, Yanhong Ji
BACKGROUND: Occult hepatitis B virus (HBV) infection (OBI) is defined as HBV DNA detection in serum or in the liver by sensitive diagnostic tests in HBV surface antigen (HBsAg) negative patients with or without serologic markers of previous HBV exposure. Because the human leukocyte antigen (HLA) system is an integral component of the immune response, we hypothesized that the highly polymorphic HLA genes were the key determinants of HBV persistence and clearance. The present study aimed to calculate the allelic frequency of HLA loci and investigate the association between HLA alleles and the outcome of OBI in Shaanxi Han population in the northwest of China...
September 2017: Journal of Gene Medicine
https://www.readbyqxmd.com/read/28903779/hepatitis-delta-virological-and-clinical-aspects
#16
REVIEW
Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira Dos Santos, Juan Miguel Villalobos Salcedo, Deusilene Souza Vieira
There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection...
September 13, 2017: Virology Journal
https://www.readbyqxmd.com/read/28875955/efficacy-of-real-world-entecavir-therapy-in-treatment-na%C3%A3-ve-chronic-hepatitis-b-patients
#17
Yan-Di Xie, Hui Ma, Bo Feng, Lai Wei
Background: Entecavir (ETV) has been shown to be effective in randomized controlled trials in highly selected patients with hepatitis B virus (HBV) infection. This study aimed to evaluate the efficacy of ETV in chronic hepatitis B (CHB) patients in the real-world setting. Methods: A total of 233 treatment-naïve, CHB patients who received at least 12 months of ETV treatment were included in this retrospective study. Rates of virological response (VR), hepatitis B s antigen (HBsAg) loss, hepatitis B e antigen (HBeAg) clearance/seroconversion, virological breakthrough, cirrhosis, and hepatocellular carcinoma were evaluated...
September 20, 2017: Chinese Medical Journal
https://www.readbyqxmd.com/read/28869890/development-of-anti-hepatitis-b-surface-hbs-antibodies-after-hbs-antigen-loss-in-hiv-hepatitis-b-virus-co-infected-patients
#18
Anders Boyd, Laetitia Canini, Joël Gozlan, Caroline Lascoux-Combe, Patrick Miailhes, Laurent Fonquernie, Pierre-Marie Girard, Karine Lacombe
BACKGROUND: Hepatitis B surface antigen (HBsAg)-seroconversion, or loss of HBsAg and acquisition of anti-hepatitis B surface (HBs) antibodies, defines functional cure of chronic hepatitis B virus (HBV) infection. After HBsAg-loss, little is known regarding the development of anti-HBs antibodies and even less so in individuals co-infected with HIV. OBJECTIVES: To determine anti-HBs antibody kinetics after HBsAg-loss and explore determinants of HBsAg-seroconversion in HIV-HBV co-infected patients...
August 25, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/28856289/recommendations-for-the-treatment-of-hepatitis-b-in-2017
#19
REVIEW
Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Jacek Juszczyk, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Simon, Krzysztof Tomasiewicz, Marta Wawrzynowicz-Syczewska
The therapeutic goal which is currently unfrequent but realistic in HBV infected patients is sustained HBsAg clearance. It is preceded by the loss or significant suppression of HBV replication and leads to inhibition of the progression of liver fibrosis, normalization of biochemical indicators of liver damage, reduction in the risk of hepatocellular carcinoma, prolongation of survival, prevention of HBV infection in the transplanted organ in post-transplant patients, enhancement of the quality of life, inhibition or reversal of extrahepatic changes associated with HBV infection, and halting of the spread of HBV infections...
June 2017: Clinical and experimental hepatology
https://www.readbyqxmd.com/read/28822954/the-variability-of-hepatitis-b-envelope-is-associated-with-hbs-antigen-persistence-in-either-chronic-or-acute-hbv-genotype-a-infection
#20
Marine Eschlimann, Brice Malvé, Aurélie Velay, Honorine Fenaux, Sibel Berger, Jean-Pol Frippiat, Fabien Zoulim, Mouni Bensenane, Jean-Pierre Bronowicki, François Goehringer, Thierry May, Hélène Jeulin, Evelyne Schvoerer
BACKGROUND: More than 240 million people are chronically infected by hepatitis B virus (HBV) worldwide. Envelope proteins play a crucial role in viral cellular entry and immune recognition. The loss of HBs antigen (HBsAg) correlated with a good clinical prognosis is rarely achieved with or without treatment (3-16%). OBJECTIVES: HBV envelope variability was investigated according to HBsAg persistence. STUDY DESIGN: The cohort consisted of 15 HBV genotype A-infected patients divided into "resolvers", with HBsAg clearance, and "non-resolvers", with HBsAg persistence and in subgroups: acute (n=5, AHBV) or chronic infection (n=4, CHBV) and HBV/HIV coinfection (n=6, CHBV/HIV)...
August 5, 2017: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
keyword
keyword
42773
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"